Abstracts tagged "juvenile myositis and outcomes"

Abstract Number: 1275 • 2017 ACR/ARHP Annual Meeting
101 Juvenile Myositis Patients Characterized By Myositis Specific Antibodies: Disease Activity and Damage over 60 Months
Lauren M. Pachman^1,2, Megan L. Curran³, Gabrielle A. Morgan⁴, IRA Targoff⁵, Hua Huang⁶, Dong Xu⁷ and Chiang-Ching Huang⁸, ¹Cure JM Program of Excellence in Juvenile Myositis Research, Stanley Manne Children’s Research Institute, affiliated with Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, ²Pediatric Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ³Pediatric Immunology/Rheum, UCSF, San Francisco, CA, ⁴Cure JM Program of Excellence in Myositis Research, Chicago, IL, ⁵internal Medicine, The University of Oklaoma, Norman, OK, ⁶Joseph J. Zilber School of Public Health, Milwaukee, WI, ⁷Pediatric Rheumatology, Stanley Manne Research Center, Chicago, IL, ⁸Biostatistics, Joseph J. Zilber School of Public Health,, Milwaukee, WI
Background/Purpose: The impetus for this investigation was the specific questions from parents of JM patients pertaining to the physician’s expectations about their child’s disease course.…
Abstract Number: 1367 • 2016 ACR/ARHP Annual Meeting
Long-Term Outcomes and Their Predictors in Patients with Juvenile Idiopathic Inflammatory Myopathies of Adult Age: A Referral Population Study
Sam Serafi¹, Vladislav Tsaltskan², Anna Yakovleva³, Heidi Sami¹, Frederick W. Miller⁴, Rodolfo Curiel¹, Olcay Y. Jones^1,5 and Lisa G. Rider^1,4, ¹Rheumatology, George Washington University, Washington, DC, ²Internal Medicine, George Washington University, Washington, DC, ³Department of Microbiology, Immunology, and Tropical Medicine., George Washington University, Washington, DC, ⁴Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, NIH, Bethesda, MD, ⁵Pediatrics, Walter Reed National Military Medical Center, Bethesda, MD
Background/Purpose: To investigate the long-term outcomes and prognostic factors for pts with juvenile-onset idiopathic inflammatory myopathies (JIIM) who are currently adults. Methods: Adults with JIIM…
Abstract Number: 1369 • 2016 ACR/ARHP Annual Meeting
Features Distinguishing Clinically Hypo- and Amyopathic Juvenile Dermatomyositis (CAJDM) from Juvenile Dermatomyositis (JDM)
Gulnara Mamyrova¹, Takayuki Kishi², Nastaran Bayat², Ira N. Targoff³, Lan Wu², Olcay Y. Jones^1,4, Rodolfo Curiel¹, Frederick W. Miller² and Lisa G. Rider^1,2, ¹Rheumatology, George Washington University, Washington, DC, ²Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, NIH, Bethesda, MD, ³University of Oklahoma, Oklahoma City, OK, ⁴Pediatrics, Walter Reed National Military Medical Center, Bethesda, MD
Background/Purpose: Clinically Amyopathic Juvenile Dermatomyositis (CAJDM) is a distinct clinical phenotype of JDM in which patients (pts) often have characteristic JDM rashes with little…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].